Form 4: Rhythm Pharmaceuticals Executive Yann Mazabraud Reports Stock Option Grant and RSU Vesting

EVP, Head of International at Rhythm Pharmaceuticals, Yann Mazabraud, reports the vesting of restricted stock units and the grant of stock options.

Summary

• Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals, filed a Form 4 on February 19, 2025, reporting transactions related to Rhythm Pharmaceuticals, Inc. stock.
• On February 14, 2025, Mazabraud was granted 60,000 stock options with an exercise price of $56.69, expiring on February 13, 2035.
• These options vest in 16 substantially equal installments every three months following the grant date.
• Also on February 14, 2025, Mazabraud was granted 40,000 restricted stock units (RSUs) that vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029.
• On February 16, 2025, 5,500 restricted stock units vested.
• Following these transactions, Mazabraud directly owns 40,370 shares of common stock, 60,000 stock options, and 16,500 restricted stock units.
• Mazabraud has granted power of attorney to David Meeker, M.D., Jim Flaherty, Hunter Smith and Stephen Vander Stoep to execute and file forms related to securities transactions on his behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports routine stock transactions by an executive. The grants are positive for incentivizing the executive, but the filing itself is a standard procedure.

Positives

• The grant of stock options and RSUs to a key executive aligns their interests with those of the shareholders, incentivizing performance and long-term value creation.

Industry Context

Stock option and RSU grants are common practices in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants and RSU vesting schedules are typical compensation components for executives in publicly traded pharmaceutical companies.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize similar equity-based compensation plans to attract and retain talent.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance.

Stakeholder Impact

• The stock option and RSU grants could have a positive impact on shareholders by incentivizing the executive to improve company performance.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Rhythm Pharmaceuticals, Stock Options, Restricted Stock Units, Insider Trading, Yann Mazabraud, Beneficial Ownership